SA98190747B1 - توليفة من عوامل فعالة وبصفة خاصة tetrahydropyridine وعوامل مثبطة لانزيم acetylcholinesterase لعلاج عته الشيخويخة مثل عته الزهايمر alzheimer - Google Patents

توليفة من عوامل فعالة وبصفة خاصة tetrahydropyridine وعوامل مثبطة لانزيم acetylcholinesterase لعلاج عته الشيخويخة مثل عته الزهايمر alzheimer Download PDF

Info

Publication number: SA98190747B1
Authority: SA; Saudi Arabia
Prior art keywords: tetrahydropyridine; trifluoromethylphenyl; ethyl; biphenylyl; alkyl
Prior art date: 1997-11-14

Application number

SA98190747A

Other languages

Arabic (ar)

English (en)

Inventor

جان بيري مافراند

جان بول تيرانوفا

فيليب سوبري

Original Assignee

سانوفي

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-14

Filing date

1998-11-14

Publication date

2006-11-04

1997-11-14 Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr

1997-11-14 Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr

1998-11-14 Application filed by سانوفي filed Critical سانوفي

2006-11-04 Publication of SA98190747B1 publication Critical patent/SA98190747B1/ar

Links

239000013543 active substance Substances 0.000 title claims abstract description 26
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title claims description 38
238000011282 treatment Methods 0.000 title claims description 14
239000000544 cholinesterase inhibitor Substances 0.000 title claims description 11
208000024827 Alzheimer disease Diseases 0.000 title claims description 6
206010039966 Senile dementia Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 42
150000003839 salts Chemical class 0.000 claims abstract description 35
125000000217 alkyl group Chemical group 0.000 claims abstract description 28
125000003545 alkoxy group Chemical group 0.000 claims abstract description 17
-1 phenylthio, phenylsulphonyl Chemical group 0.000 claims abstract description 15
125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 14
229910052736 halogen Inorganic materials 0.000 claims abstract description 14
150000002367 halogens Chemical class 0.000 claims abstract description 13
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 12
102000012440 Acetylcholinesterase Human genes 0.000 claims abstract description 11
108010022752 Acetylcholinesterase Proteins 0.000 claims abstract description 11
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
239000001257 hydrogen Substances 0.000 claims abstract description 11
229940022698 acetylcholinesterase Drugs 0.000 claims abstract description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
238000006467 substitution reaction Methods 0.000 claims abstract description 6
239000004615 ingredient Substances 0.000 claims abstract description 5
125000004442 acylamino group Chemical group 0.000 claims abstract description 4
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims abstract description 4
125000004181 carboxyalkyl group Chemical group 0.000 claims abstract description 4
125000006310 cycloalkyl amino group Chemical group 0.000 claims abstract description 4
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims abstract description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 4
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 4
125000005504 styryl group Chemical group 0.000 claims abstract description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 3
125000005843 halogen group Chemical group 0.000 claims abstract description 3
125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 9
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 3
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract 3
125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
230000002401 inhibitory effect Effects 0.000 claims abstract 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 27
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 18
238000009472 formulation Methods 0.000 claims description 12
206010012289 Dementia Diseases 0.000 claims description 9
229960003530 donepezil Drugs 0.000 claims description 9
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 7
239000003112 inhibitor Substances 0.000 claims description 6
230000002195 synergetic effect Effects 0.000 claims description 6
229960001685 tacrine Drugs 0.000 claims description 6
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 5
125000003282 alkyl amino group Chemical group 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
GAPOASFZXBWUGS-UHFFFAOYSA-N 2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone Chemical compound C[Si](C)(C)C1=CC=CC(C(=O)C(F)(F)F)=C1 GAPOASFZXBWUGS-UHFFFAOYSA-N 0.000 claims description 3
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 3
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
239000011885 synergistic combination Substances 0.000 claims description 3
WALYRZRLDDOTJG-UHFFFAOYSA-N 2-chloro-6-[1-[2-(4-phenylphenyl)ethyl]-3,6-dihydro-2h-pyridin-4-yl]pyridine Chemical compound ClC1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3C=CC=CC=3)CC=2)=N1 WALYRZRLDDOTJG-UHFFFAOYSA-N 0.000 claims description 2
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 claims description 2
NVJCKHLCZVJYHR-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-[2-(4-phenylphenyl)ethyl]-3,6-dihydro-2h-pyridine Chemical compound C1=CC(F)=CC=C1C(CC1)=CCN1CCC1=CC=C(C=2C=CC=CC=2)C=C1 NVJCKHLCZVJYHR-UHFFFAOYSA-N 0.000 claims description 2
HLVVITIHAZBPKB-UHFFFAOYSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 HLVVITIHAZBPKB-UHFFFAOYSA-N 0.000 claims description 2
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 claims description 2
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 2
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
229950010753 eptastigmine Drugs 0.000 claims description 2
229960003980 galantamine Drugs 0.000 claims description 2
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 claims description 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 2
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 claims description 2
229960001952 metrifonate Drugs 0.000 claims description 2
230000003551 muscarinic effect Effects 0.000 claims description 2
229960001697 physostigmine Drugs 0.000 claims description 2
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims description 2
239000002464 receptor antagonist Substances 0.000 claims description 2
229940044551 receptor antagonist Drugs 0.000 claims description 2
229960004136 rivastigmine Drugs 0.000 claims description 2
NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims description 2
229950001843 velnacrine Drugs 0.000 claims description 2
229950004402 zifrosilone Drugs 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
125000005111 carboxyalkoxy group Chemical group 0.000 claims 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
230000001681 protective effect Effects 0.000 claims 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
HAKSOKWVNPZVNM-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine;hydrochloride Chemical compound Cl.C1CNC=CC1 HAKSOKWVNPZVNM-UHFFFAOYSA-N 0.000 claims 1
102000004190 Enzymes Human genes 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
230000032683 aging Effects 0.000 claims 1
239000005515 coenzyme Substances 0.000 claims 1
229940088598 enzyme Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000002664 nootropic agent Substances 0.000 claims 1
239000003223 protective agent Substances 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
230000001228 trophic effect Effects 0.000 claims 1
238000002636 symptomatic treatment Methods 0.000 abstract description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 2
150000002431 hydrogen Chemical class 0.000 abstract 2
101100496114 Caenorhabditis elegans clc-2 gene Proteins 0.000 abstract 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000000694 effects Effects 0.000 description 7
WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 5
108010025020 Nerve Growth Factor Proteins 0.000 description 4
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
229960004528 vincristine Drugs 0.000 description 4
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003902 lesion Effects 0.000 description 3
230000015654 memory Effects 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
238000011084 recovery Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
102000015336 Nerve Growth Factor Human genes 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
206010027175 memory impairment Diseases 0.000 description 2
238000000034 method Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
230000000508 neurotrophic effect Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000004036 social memory Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
RMKUOCBJRZODFU-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2,8-dimethyl-3-methylidene-1-oxa-8-azaspiro[4.5]decane Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C(=C)C(C)OC21CCN(C)CC2 RMKUOCBJRZODFU-LREBCSMRSA-N 0.000 description 1
PSRPKRDUWXFVQS-GNAZCLTHSA-N (3s,4r)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]thiolan-2-one;phosphoric acid Chemical compound OP(O)(O)=O.C1SC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C PSRPKRDUWXFVQS-GNAZCLTHSA-N 0.000 description 1
SBCXBWBXWKVIFK-PBBCPHEYSA-N (e)-but-2-enedioic acid;(3r)-3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane Chemical compound OC(=O)\C=C\C(O)=O.C1CC2[C@@H](OCC#C)CN1CC2 SBCXBWBXWKVIFK-PBBCPHEYSA-N 0.000 description 1
CLAAWCXSVHYZOF-UHFFFAOYSA-N 1-[2-(2-chloro-4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C(=CC(=CC=3)C=3C=CC=CC=3)Cl)CC=2)=C1 CLAAWCXSVHYZOF-UHFFFAOYSA-N 0.000 description 1
QRXBOJSFBITNAZ-UHFFFAOYSA-N 1-[2-(3,4-dipropylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1=C(CCC)C(CCC)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 QRXBOJSFBITNAZ-UHFFFAOYSA-N 0.000 description 1
IYEVNGCQLBOKSD-UHFFFAOYSA-N 1-[2-(3-fluoro-4-phenylphenyl)propyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C=1C=C(C=2C=CC=CC=2)C(F)=CC=1C(C)CN(CC=1)CCC=1C1=CC=CC(C(F)(F)F)=C1 IYEVNGCQLBOKSD-UHFFFAOYSA-N 0.000 description 1
QQYINFSTLSPFDL-UHFFFAOYSA-N 1-[2-(3-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C(C=CC=3)C=3C=CC=CC=3)CC=2)=C1 QQYINFSTLSPFDL-UHFFFAOYSA-N 0.000 description 1
RMTTZCBMBRCQRV-UHFFFAOYSA-N 1-[2-(4-benzylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(CC=4C=CC=CC=4)=CC=3)CC=2)=C1 RMTTZCBMBRCQRV-UHFFFAOYSA-N 0.000 description 1
WCLDJGHFRWOPJG-UHFFFAOYSA-N 1-[2-(4-butoxyphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1=CC(OCCCC)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 WCLDJGHFRWOPJG-UHFFFAOYSA-N 0.000 description 1
RWPHWFAGKMQMNQ-UHFFFAOYSA-N 1-[2-(4-butylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1=CC(CCCC)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 RWPHWFAGKMQMNQ-UHFFFAOYSA-N 0.000 description 1
VALBFTWRAPRFAG-UHFFFAOYSA-N 1-[2-(4-cyclohexylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C3CCCCC3)CC=2)=C1 VALBFTWRAPRFAG-UHFFFAOYSA-N 0.000 description 1
ABBQYZDVGHQSMF-UHFFFAOYSA-N 1-[2-(4-phenoxyphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(OC=4C=CC=CC=4)=CC=3)CC=2)=C1 ABBQYZDVGHQSMF-UHFFFAOYSA-N 0.000 description 1
CNEWKIDCGDXBDE-UHFFFAOYSA-N 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3C=CC=CC=3)CC=2)=C1 CNEWKIDCGDXBDE-UHFFFAOYSA-N 0.000 description 1
SNFRDRZUPBHGJT-UHFFFAOYSA-N 1-[2-[3-chloro-4-(3-chlorophenyl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C(Cl)C(=CC=3)C=3C=C(Cl)C=CC=3)CC=2)=C1 SNFRDRZUPBHGJT-UHFFFAOYSA-N 0.000 description 1
PUPRBDYGCRMPKP-UHFFFAOYSA-N 1-[2-[4-(3-chloro-4-fluorophenyl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1=C(Cl)C(F)=CC=C1C(C=C1)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 PUPRBDYGCRMPKP-UHFFFAOYSA-N 0.000 description 1
XNACPFPQUNDICM-UHFFFAOYSA-N 1-[2-[4-(3-chlorophenyl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3C=C(Cl)C=CC=3)CC=2)=C1 XNACPFPQUNDICM-UHFFFAOYSA-N 0.000 description 1
CPNHRQSEIFVLQO-UHFFFAOYSA-N 1-[2-[4-(4-fluorophenyl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C1=CC(F)=CC=C1C(C=C1)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 CPNHRQSEIFVLQO-UHFFFAOYSA-N 0.000 description 1
VZTXRLKHUFPMRC-UHFFFAOYSA-N 1-[2-methyl-2-(4-phenylphenyl)propyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(C)(C)CN(CC=1)CCC=1C1=CC=CC(C(F)(F)F)=C1 VZTXRLKHUFPMRC-UHFFFAOYSA-N 0.000 description 1
DNJYJMDQLURVBB-UHFFFAOYSA-N 2-(2-bromoethyl)naphthalene Chemical compound C1=CC=CC2=CC(CCBr)=CC=C21 DNJYJMDQLURVBB-UHFFFAOYSA-N 0.000 description 1
XQHBVCWPLIENDJ-UHFFFAOYSA-N 2-chloro-6-[1-[2-(4-cyclohexylphenyl)ethyl]-3,6-dihydro-2h-pyridin-4-yl]pyridine Chemical compound ClC1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C3CCCCC3)CC=2)=N1 XQHBVCWPLIENDJ-UHFFFAOYSA-N 0.000 description 1
GKZWPTSMKCVFMZ-UHFFFAOYSA-N 2-chloro-6-[1-[2-[4-(2-methylpropyl)phenyl]propyl]-3,6-dihydro-2h-pyridin-4-yl]pyridine Chemical compound C1=CC(CC(C)C)=CC=C1C(C)CN1CC=C(C=2N=C(Cl)C=CC=2)CC1 GKZWPTSMKCVFMZ-UHFFFAOYSA-N 0.000 description 1
UNYWJQCJOSOOBE-UHFFFAOYSA-N 2-ethyl-8-methyl-1-oxa-8-azaspiro[4.5]decan-3-one Chemical compound C1C(=O)C(CC)OC21CCN(C)CC2 UNYWJQCJOSOOBE-UHFFFAOYSA-N 0.000 description 1
CWEHWZPCDBRUNO-WLHGVMLRSA-N 3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)propan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C=1C=C2CCCCNC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 CWEHWZPCDBRUNO-WLHGVMLRSA-N 0.000 description 1
IFYKRMQORZOMNY-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCNCC=2)=C1 IFYKRMQORZOMNY-UHFFFAOYSA-N 0.000 description 1
ZWLXREOJYZDTTE-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1-[2-[4-[2-(trifluoromethyl)phenyl]phenyl]ethyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3C(=CC=CC=3)C(F)(F)F)CC=2)=C1 ZWLXREOJYZDTTE-UHFFFAOYSA-N 0.000 description 1
JJZHILQQKTVDMU-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1-[2-[4-[3-(trifluoromethyl)phenyl]phenyl]ethyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3C=C(C=CC=3)C(F)(F)F)CC=2)=C1 JJZHILQQKTVDMU-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
241000490494 Arabis Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241001559542 Hippocampus hippocampus Species 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 description 1
ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940039856 aricept Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
MTCMTKNMZCPKLX-UHFFFAOYSA-N chembl359570 Chemical compound N=1OC=2C=C3NC(=O)CC3=CC=2C=1CCC(CC1)CCN1CC1=CC=CC=C1 MTCMTKNMZCPKLX-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229950010480 icopezil Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
239000000181 nicotinic agonist Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
XVFJONKUSLSKSW-JTQLQIEISA-N talsaclidine Chemical compound C1CC2[C@@H](OCC#C)CN1CC2 XVFJONKUSLSKSW-JTQLQIEISA-N 0.000 description 1
229950001645 talsaclidine Drugs 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 description 1
229950006755 xanomeline Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SA98190747A 1997-11-14 1998-11-14 توليفة من عوامل فعالة وبصفة خاصة tetrahydropyridine وعوامل مثبطة لانزيم acetylcholinesterase لعلاج عته الشيخويخة مثل عته الزهايمر alzheimer SA98190747B1 (ar)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9714324A FR2771006B1 (fr)	1997-11-14	1997-11-14	Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr)	1997-11-14	1997-11-14	Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number	Publication Date
SA98190747B1 true SA98190747B1 (ar)	2006-11-04

Family

ID=26233932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SA98190747A SA98190747B1 (ar)	1997-11-14	1998-11-14	توليفة من عوامل فعالة وبصفة خاصة tetrahydropyridine وعوامل مثبطة لانزيم acetylcholinesterase لعلاج عته الشيخويخة مثل عته الزهايمر alzheimer

Country Status (27)

Country	Link
EP (1)	EP1030671A1 (et)
JP (1)	JP2001523642A (et)
KR (1)	KR100599350B1 (et)
CN (1)	CN1243540C (et)
AU (1)	AU743228B2 (et)
BG (1)	BG64819B1 (et)
BR (1)	BR9814035A (et)
CA (1)	CA2309966A1 (et)
CO (1)	CO4980891A1 (et)
DZ (1)	DZ2649A1 (et)
EA (1)	EA003255B1 (et)
EE (1)	EE04235B1 (et)
HU (1)	HUP0100098A3 (et)
ID (1)	ID24933A (et)
IL (2)	IL136122A0 (et)
IS (1)	IS5482A (et)
MY (1)	MY120461A (et)
NO (1)	NO20002450L (et)
NZ (1)	NZ504420A (et)
OA (1)	OA11464A (et)
PL (1)	PL194597B1 (et)
SA (1)	SA98190747B1 (et)
SK (1)	SK286040B6 (et)
TR (1)	TR200001262T2 (et)
TW (1)	TW585766B (et)
UY (1)	UY25247A1 (et)
WO (1)	WO1999025363A1 (et)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0311780B8 (pt) *	2002-06-14	2021-05-25	Toyama Chemical Co Ltd	composição farmacêutica para melhorar a função cerebral
DE60328198D1 (de) *	2002-08-07	2009-08-13	Novartis Ag	Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
CN1520818A (zh) *	2003-02-09	2004-08-18	山东绿叶天然药物研究开发有限公司	治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en)	2004-12-27	2013-07-09	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
EP4023294A1 (en)	2014-01-31	2022-07-06	Cognition Therapeutics, Inc.	Isoindoline compositions and methods for treating alzheimer's disease
KR102614814B1 (ko)	2017-05-15	2023-12-20	카그니션 테라퓨틱스, 인코퍼레이티드	신경변성 질환 치료용 조성물
WO2019182319A1 (ko) *	2018-03-20	2019-09-26	(주)인벤티지랩	인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
KR102224918B1 (ko)	2018-03-20	2021-03-09	(주)인벤티지랩	도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
CN109265391B (zh) *	2018-11-13	2021-11-19	枣庄学院	联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2662355B1 (fr) *	1990-05-22	1994-11-10	Sanofi Sa	Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) *	1991-02-14	1995-09-26	The Mount Sinai School Of Medicine Of The City Of New York	Method and composition for the treatment of apathy-amotivation syndrome
CN1126546C (zh) *	1995-03-06	2003-11-05	英特纽隆制剂药有限公司	使用胞磷胆碱减少梗塞面积
FR2736053B1 (fr) *	1995-06-28	1997-09-19	Sanofi Sa	Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

1998
- 1998-10-26 CO CO98062479A patent/CO4980891A1/es unknown
- 1998-10-28 TW TW087117874A patent/TW585766B/zh not_active IP Right Cessation
- 1998-11-09 EE EEP200000290A patent/EE04235B1/et not_active IP Right Cessation
- 1998-11-09 EP EP98954538A patent/EP1030671A1/fr not_active Withdrawn
- 1998-11-09 IL IL13612298A patent/IL136122A0/xx not_active IP Right Cessation
- 1998-11-09 KR KR1020007005231A patent/KR100599350B1/ko not_active Expired - Fee Related
- 1998-11-09 CA CA002309966A patent/CA2309966A1/en not_active Abandoned
- 1998-11-09 BR BR9814035-3A patent/BR9814035A/pt not_active Application Discontinuation
- 1998-11-09 CN CNB988130947A patent/CN1243540C/zh not_active Expired - Fee Related
- 1998-11-09 HU HU0100098A patent/HUP0100098A3/hu unknown
- 1998-11-09 SK SK711-2000A patent/SK286040B6/sk unknown
- 1998-11-09 WO PCT/FR1998/002384 patent/WO1999025363A1/fr not_active Ceased
- 1998-11-09 PL PL98340500A patent/PL194597B1/pl not_active IP Right Cessation
- 1998-11-09 JP JP2000520796A patent/JP2001523642A/ja not_active Withdrawn
- 1998-11-09 AU AU11609/99A patent/AU743228B2/en not_active Ceased
- 1998-11-09 NZ NZ504420A patent/NZ504420A/en unknown
- 1998-11-09 TR TR2000/01262T patent/TR200001262T2/xx unknown
- 1998-11-09 EA EA200000412A patent/EA003255B1/ru not_active IP Right Cessation
- 1998-11-09 ID IDW20000860A patent/ID24933A/id unknown
- 1998-11-11 DZ DZ980259A patent/DZ2649A1/xx active
- 1998-11-12 UY UY25247A patent/UY25247A1/es not_active IP Right Cessation
- 1998-11-14 SA SA98190747A patent/SA98190747B1/ar unknown
- 1998-11-14 MY MYPI98005180A patent/MY120461A/en unknown
2000
- 2000-05-09 IS IS5482A patent/IS5482A/is unknown
- 2000-05-11 BG BG104428A patent/BG64819B1/bg unknown
- 2000-05-11 NO NO20002450A patent/NO20002450L/no unknown
- 2000-05-12 OA OA1200000141A patent/OA11464A/en unknown
- 2000-05-14 IL IL136122A patent/IL136122A/en unknown

Also Published As

Publication number	Publication date
WO1999025363A1 (fr)	1999-05-27
JP2001523642A (ja)	2001-11-27
TW585766B (en)	2004-05-01
IL136122A0 (en)	2001-05-20
EE200000290A (et)	2001-06-15
EA200000412A1 (ru)	2000-12-25
CA2309966A1 (en)	1999-05-27
BG104428A (en)	2001-08-31
AU743228B2 (en)	2002-01-24
TR200001262T2 (tr)	2001-01-22
DZ2649A1 (fr)	2004-12-28
AU1160999A (en)	1999-06-07
NZ504420A (en)	2003-08-29
CN1243540C (zh)	2006-03-01
SK286040B6 (sk)	2008-01-07
PL340500A1 (en)	2001-02-12
KR100599350B1 (ko)	2006-07-12
MY120461A (en)	2005-10-31
HUP0100098A2 (hu)	2001-07-30
IL136122A (en)	2006-07-05
SK7112000A3 (en)	2000-10-09
IS5482A (is)	2000-05-09
EP1030671A1 (fr)	2000-08-30
OA11464A (en)	2003-11-18
HUP0100098A3 (en)	2001-12-28
CN1285742A (zh)	2001-02-28
BR9814035A (pt)	2000-09-26
BG64819B1 (bg)	2006-05-31
EE04235B1 (et)	2004-02-16
PL194597B1 (pl)	2007-06-29
UY25247A1 (es)	2001-05-31
KR20010032099A (ko)	2001-04-16
CO4980891A1 (es)	2000-11-27
NO20002450L (no)	2000-07-14
NO20002450D0 (no)	2000-05-11
EA003255B1 (ru)	2003-02-27
ID24933A (id)	2000-08-31

Publication	Publication Date	Title
DE69231395T3 (de)	2005-07-21	Neue medizinische Indikation für Tachykinin-Antagonisten
US6455544B1 (en)	2002-09-24	Use of cholinesterase inhibitors to treat disorders of attention
EP0216555B1 (en)	1992-09-02	Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
AU2004283425B2 (en)	2010-07-08	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
WO2008112525A2 (en)	2008-09-18	Treatment of lysosomal storage diseases
AT3185U2 (de)	1999-11-25	Paroxetinmethansulfonat
US20090192142A1 (en)	2009-07-30	Use of carbamazepine derivatives for the treatment of agitation in dementia patients
SA98190747B1 (ar)	2006-11-04	توليفة من عوامل فعالة وبصفة خاصة tetrahydropyridine وعوامل مثبطة لانزيم acetylcholinesterase لعلاج عته الشيخويخة مثل عته الزهايمر alzheimer
WO2002038155A1 (en)	2002-05-16	Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
US20030092737A1 (en)	2003-05-15	Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
HU183119B (en)	1984-04-28	Process for producing analgesic and tone-delivering compositions containing quinazoline derivatives and benzothiadiazol derivatives
JPH10167969A (ja)	1998-06-23	姑息的腫瘍療法でのドーパミンレセプター−アンタゴニストの使用
MXPA00004600A (en)	2001-05-07	Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CZ20001734A3 (cs)	2000-08-16	Farmaceutická kompozice a její použití
HK1090543B (en)	2009-09-04	Use of carbamazepine derivatives for the treatment of agitation in dementia patients
FR2771006A1 (fr)	1999-05-21	Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR2771007A1 (fr)	1999-05-21	Association de principes actifs pour le traitement de la demence senile du type alzheimer
EP2453890A1 (en)	2012-05-23	Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
JPH0132806B2 (et)	1989-07-10